UNSPSC 51421502: Timobesone

This classification denotes a therapeutic glucocorticoid with the molecular formula C22H29FO4S, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 97TVB2O56G, chemically known as s-methyl 9-fluoro-11beta,17-dihydroxy-16beta-methyl-3-oxoandrosta-1,4-diene-17beta-carbothioate but generally known as timobesone acetate, which bears US NIH Compound Identifier 70691439. European Medicines Agency schedules timobesone in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB11067MIG.

Most nations schedule timobesone under HS 29372200 and SITC 54153. As of Q4 2014, TIMOBESONE remains the US FDA Preferred Term for this commodity. SMILES: CC1CC2C3CCC4=CC(=O)C=CC4(C3(C(CC2(C1(C(=O)SC)OC(=O)C)C)O)F)C.

UNSPSC 51421502 Timobesone, a Commodity code, maps to state and local procurement of pharmaceutical products and related health-system supplies, though the recent opportunities tagged under it diverge significantly from the code's nominal scope. Seminole County, Florida issued IFB 60459723LAS in June 2026 to procure 1,900 units of Naloxone and 800 Safe Drug Deactivation Systems annually through competitive sealed bidding, with quarterly deliveries to the county's Community Health Building and a two-year initial term plus one-year renewal option. The Texas Health and Human Services Commission posted RFI HHS0017013 in April 2026 to gather vendor capabilities regarding direct-to-manufacturer prescription programs outside traditional pharmacy benefit manager and group purchasing organization channels. Neither opportunity directly reflects timobesone procurement; the code shows minimal recent activity aligned with its nominal product scope, with issuing bodies spanning county health departments and state health agencies pursuing broader pharmacy benefit, drug-deactivation, and alternative prescription-fulfillment initiatives rather than timobesone specifically.

Activity appears concentrated in Florida and Texas, with Seminole County's naloxone and drug-deactivation systems bid representing the only concrete procurement with fixed quantities and response deadlines, while the Texas RFI functions as exploratory market intelligence rather than a formal competitive solicitation. The Seminole County opportunity requires vendors to submit electronic bids by July 26, 2023 (note: posted date appears to be June 30, 2026, creating a date discrepancy in the source), include all shipping and delivery costs, maintain drug-free workplace and E-Verify compliance, and carry workers' compensation, commercial general liability, and professional liability insurance. The Texas RFI has no set-aside designations, budget range, or formal evaluation criteria at this exploratory stage. Given the mismatch between the code's nominal scope and the actual health-system procurement activity appearing under it, firms should verify whether opportunities tagged to this code reflect their actual product or service lines before investing in bid pursuit.